Anti-angiogenic therapy for malignant glioma

Japanese Journal of Cancer and Chemotherapy

Volumn 41, Issue 2, 2014, Pages 141-147

  Nagane, Motoo ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bevacizumab; Glioblastoma; Glioma; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; PLACEBO; TEMOZOLOMIDE;

ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; GLIOBLASTOMA; HUMAN; MONOTHERAPY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; GLIOMA; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84899018005     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5): 459-466, 2009.
2. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21): 1182-1186, 1971.
3. Jansen M, de Witt Hamer PC, Witmer AN, et al: Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas. Brain Res Brain Res Rev 45 (3): 143-163, 2004. (Pubitemid 38802868)
4. Chaudhry IH, O'Donovan DG, Brenchley PE, et al: Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 39(4): 409-415, 2001. (Pubitemid 32990094)
5. Zhou YH, Tan F, Hess KR, et al: The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res 9(9): 3369-3375, 2003. (Pubitemid 37082732)
6. Chamberlain MC: Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer 116(17): 3988-3999, 2010.
7. Verhoeff JJ, van Tellingen O, Claes A, et al: Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 9: 444, 2009.
8. Yuan F, Chen Y, Dellian M, et al: Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93(25): 14765-14770, 1996. (Pubitemid 26419043)
9. Friedman HS, Prados MD, Wen PY, et al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27 (28): 4733-4740, 2009.
10. Kreisl TN, Kim L, Moore K. et al: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5): 740-745, 2009.
11. Ballman KV, Buckner JC, Brown PD. et al: The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 9(1): 29-38, 2007. (Pubitemid 46543486)
12. Lamborn KR, Yung WK, Chang SM, et al: Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10 (2): 162-170, 2008.
13. Wong ET, Hess KR, Gleason MJ, et al: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17(8): 2572-2578, 1999. (Pubitemid 29368260)
14. Nagane M, Nishikawa R, Narita Y, et al: Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn J Clin Oncol 42(10): 887-895, 2012.
15. Chinot OL, de La Motte Rouge T, Moore N, et al: A V Aglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 28(4): 334-340, 2011.
16. Wick W, Cloughesy TF, Nishikawa R, et al: Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AVAglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM). J Clin Oncol 31 (15s): abstr 2002, 2013.
17. Gilbert MR, Dignam J, Won M, et al: RTOG 0825: phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) inpatients (Pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol 31 (18s): abstr 1, 2013.
18. Armstrong TS, Won M, Wefel JS, et al: Comprehensive impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825. J Clin Oncol 31 (15s): abstr 2003, 2013.
19. Narita Y: Drug review: safety and efficacy of bevacizumab for glioblastoma and other brain tumors. Jpn J Clin Oncol 43(6): 587-595, 2013.
20. Reardon DA, Desjardins A, Peters K, et al: Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neurooncol 103(2): 371-379, 2011.
21. Reardon DA, Desjardins A, Peters KB, et al: Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 117(23): 5351-5358, 2011.
22. Omuro A, Chan TA, Abrey LE, et al: Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol 15(2): 242-250, 2013.
23. Lai A, Tran A, Nghiemphu PL, et al: Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29(2): 142-148, 2011.
24. Weller M, Cloughesy T, Perry JR, et al: Standards of care for treatment of recurrent glioblastom - are we there yet ? Neuro Oncol 15(1): 4-27, 2013.
25. Chamberlain MC: Bevacizumab for the treatment of recurrent glioblastoma Clin Med Insights Oncol 5:117-129, 2011.
26. Claes A, Wesseling P, Jeuken J, et al: Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol Cancer Ther 7 (1): 71-78, 2008.
27. Iwamoto FM, Abrey LE, Beal K, et al: Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma Neurology 73(15): 1200-1206, 2009.
28. Norden AD, Young GS, Setayesh K, et al: Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70 (10): 779-787, 2008.
29. Quant EC, Norden AD, Drappatz J, et al: Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 11(5): 550-555, 2009.
30. Sennino B, Ishiguro-Oonuma T, Wei Y, et al: Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2:270-287, 2012.
31. You WK, Sennino B, Williamson CW, et al: VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res 71(14): 4758-4768, 2011.
32. Chamberlain MC: Radiographic patterns of relapse in glioblastoma. J Neuro Oncol 101(2): 319-323, 2011.
33. Pope WB, Xia Q, Das A, et al: Patterns of progression in patients with glioblastoma at first or second relapse treated with bevacizumab alone or in combination with irinotecan in the BRAIN study. Neuro Oncol 11(5): 626, 2009.
34. Wen PY, Macdonald DR, Reardon DA, et al: Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11): 1963-1972, 2010.
35. Nagane M, Kobayashi K, Tanaka M, et al: Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide- refractory malignant glioma to bevacizumab: preliminary report. Int J Clin Oncol: 2013. [Epub ahead of print]
36. Pope WB, Young JR and Ellingson BM: Advances in MRI assessment of gliomas and response to anti-VEGF therapy. Curr Neurol Neurosci Rep 11(3): 336-344, 2011.
37. Zuniga RM, Torcuator R, Jain R, et al: Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J Neurooncol 99(2): 237-242, 2010.